CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public ...

CEO Frank Bedu-Addo highlighted the initiation of the VERSATILE 003 Phase 3 clinical trial of Versamune HPV plus pembrolizumab for first-line recurrence and/or metastatic HPV16-positive head and neck ...

The funds will support multiple new and ongoing clinical trials of Tilt's oncolytic adenoviral therapy TILT-123.

Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three partial responses (PR), and three stable disease (SD) as best clinical ...

IO Biotech was named to Fast Company’s World’s Most Innovative Companies of 2025 list for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted ...

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for ...

Data presented at American Association for Cancer Research (AACR) Annual Meeting. In April 2025, Foghorn presented new preclinical data highlighting pipeline progress for potential first-in-class ...